ERBB2 and breast cancer: Studies of luminal B breast cancers have identified two key drivers of aggressive biology in women of African ancestry: (a) c‐myc (MYC) (Naab et al., 2018) and (b) HER2/pAKT‐coactivation (Y. Wu et al., 2008).